Molecular Mechanisms and Genetics of Human Disease

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Genetics".

Deadline for manuscript submissions: closed (30 April 2026) | Viewed by 4971

Editors


E-Mail Website
Guest Editor
Department of Pharmaceutical Sciences, College of Pharmacy, Health Professions Division, Nova Southeastern University, Fort Lauderdale, FL, USA
Interests: molecular toxicology; gene and environment interactions and gene regulation; cardiovascular pharmacology and toxicology; genomic and molecular pharmacology of cancer; pharmacogenomics; biotechnology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Biochemistry, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA
Interests: molecular genetics; genomics; epigenetics; transcriptional regulation

Special Issue Information

Dear Colleagues,

Genetic disorders vary greatly in their occurrence in different ethnic and geographic populations. For example, sickle cell anemia is more common among people of African descent, phenylketonuria is notably prevalent in Celtic and Northern European groups, Tay-Sachs disease has a higher incidence in Ashkenazi Jewish communities, and cystic fibrosis occurs more frequently in European and American Caucasian populations. Although many of these conditions have traditionally been explained as being the result of single-gene defects caused by point mutations, emerging evidence points to the critical role of larger chromosomal rearrangements (e.g., insertions, deletions, and duplications) in shaping disease etiology. Autosomal dominant neuropathies illustrate this principle particularly well. Charcot–Marie–Tooth disease type 1A (CMT1A) stems from a reciprocal duplication on chromosome seventeen, while hereditary neuropathy with a liability to pressure palsy (HNPP) arises from a corresponding deletion at the same locus. These structural variants are often the result of aberrant recombination events that can introduce either surplus or deficit copies of essential genes. Collectively, these observations indicate that genomic instability and rearrangements, rather than point mutations alone, can underpin the onset and progression of complex genetic disorders. Recently, the notion of structural rearrangements being a unifying mechanism for distinct clinical phenotypes has gained traction. Introducing copy number variations or altering gene organization can lead to both loss-of- and gain-of-function mutations, causing an extensive range of molecular and clinical outcomes. With this in mind, we invite contributions to this Special Issue that explore the molecular underpinnings of genetic disorders, especially those driven by genomic rearrangements. Of particular interest will be studies that elucidate how these structural alterations affect gene expression, protein function, and disease phenotypes, as they hold promise for advancing our understanding of pathogenesis and the development of innovative therapeutic strategies.

In this Special Issue, original research articles and reviews are welcome. Their research areas may include (but are not limited to) the following: 

  1. Genomic variation in disease onset and progression;
  2. Alteration of chromatin architecture causing aberrant transcriptional regulation;
  3. Impaired protein interactions;
  4. Structural variations (insertion/deletion, duplication, and translocations).

I look forward to receiving your contributions. 

Dr. Rais Ahmad Ansari
Dr. Ata Abbas
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • genomic rearrangement
  • genetic diseases
  • molecular mechanism
  • recombination
  • gene duplication

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 1349 KB  
Article
Functional Characterization of the VWF p.Cys2163Tyr Variant Reveals Impaired Secretion and Intracellular Processing
by Yuxin Zhang, Yingkun Zhang, Aizhen Yang, Yabei Zuo, Xiaofeng Yan, Feifei Zhang, Yan Wang, Zhiyun Niu, Fengwu Chen, Yi Wu and Jingyu Zhang
Biomolecules 2026, 16(8), 1088; https://doi.org/10.3390/biom16081088 - 25 Jul 2026
Viewed by 475
Abstract
Von Willebrand disease (VWD) is the most common inherited bleeding disorder, yet the contribution of specific VWF domains to its pathogenesis remains incompletely understood. In particular, the role of the D4 domain in VWF secretion, intracellular maturation, and multimer formation has not been [...] Read more.
Von Willebrand disease (VWD) is the most common inherited bleeding disorder, yet the contribution of specific VWF domains to its pathogenesis remains incompletely understood. In particular, the role of the D4 domain in VWF secretion, intracellular maturation, and multimer formation has not been fully elucidated. Here, we investigated the functional impact of a heterozygous p.Cys2163Tyr variant located in the D4 domain, identified in a patient with a severe bleeding phenotype, using clinical evaluation, genetic analysis, family studies, and in vitro expression assays. Laboratory testing revealed markedly reduced VWF:Ag (6.8 IU/dL), VWF:GPIbR (0.1 IU/dL), and FVIII:C levels, indicating a severe VWD phenotype in the proband. Plasma VWF multimer analysis showed a markedly reduced overall VWF signal with an almost complete absence of high-molecular-weight multimers, supporting classification of the phenotype as severe type 2A VWD. The heterozygous c.6488G>A (p.Cys2163Tyr) variant was also present in asymptomatic family members, indicating incomplete segregation with the severe phenotype and suggesting that this variant alone is insufficient to explain the proband’s disease severity. Notably, the proband’s mother exhibited mildly reduced VWF levels in the absence of this variant, suggesting the possible contribution of an additional unidentified defect or modifier affecting the maternal allele. In vitro expression demonstrated preserved intracellular VWF antigen, markedly reduced secretion of mutant VWF, and loss of high-molecular-weight VWF multimers. Together, these findings indicate that VWF p.Cys2163Tyr is a functionally deleterious variant that markedly impairs VWF secretion and high-molecular-weight multimer formation in vitro. However, the incomplete segregation observed in the family suggests that this heterozygous variant alone may not fully account for the proband’s severe type 2A VWD phenotype. Full article
(This article belongs to the Special Issue Molecular Mechanisms and Genetics of Human Disease)
Show Figures

Figure 1

Review

Jump to: Research

17 pages, 786 KB  
Review
The Promise and Pursuit of MicroRNAs for Cancer Treatment
by Camaleta Boothe, Arianna Rossi, Jenniffer Kalil and Jean J. Latimer
Biomolecules 2026, 16(8), 1086; https://doi.org/10.3390/biom16081086 - 24 Jul 2026
Viewed by 318
Abstract
In spite of at least six discrete classes of drugs available for cancer treatment, the quest for more biologic drugs continues. One type of biologic molecule that occurs naturally in the body is microRNA. MicroRNAs regulate post-transcriptional gene expression and can be under [...] Read more.
In spite of at least six discrete classes of drugs available for cancer treatment, the quest for more biologic drugs continues. One type of biologic molecule that occurs naturally in the body is microRNA. MicroRNAs regulate post-transcriptional gene expression and can be under expressed in cancer (tumor suppressor microRNAs) or over expressed (oncogenic microRNAs). Strand-specific mimics of microRNAs have been developed and used successfully in vitro, in vivo, and in clinical trials, to control multiple aspects of cancer including metastasis, apoptosis and proliferation. Each microRNA is capable of binding a specific target mRNA or mRNAs, sometimes simultaneously interfering with multiple genes in a single pathway, or binding with a single nodal mRNA. Some microRNAs can facilitate chemotherapy that has stopped working, addressing the issue of drug resistance. Without chemical modification, microRNAs are too vulnerable to have lasting therapeutic value. Chemical modifications to microRNAs have provided nuclease resistance and greater stability and are the basis for microRNA mimics that can be used therapeutically. However, without a vehicle, microRNA mimics do not cross cell membranes. These nanoparticles can cause inflammatory reactions in patients. Additional modifications that enabled microRNA mimics to cross cell membranes include substituting uracil with 5-fluorouracil. Lessons from an siRNA therapeutic called Patisiran offer a roadmap for future success for microRNAs in cancer. This review provides a historical perspective of the continuing evolution of microRNA mimics for cancer treatment. Full article
(This article belongs to the Special Issue Molecular Mechanisms and Genetics of Human Disease)
Show Figures

Figure 1

15 pages, 1207 KB  
Review
Gene Fusions as Potential Therapeutic Targets in Soft Tissue Sarcomas
by Qiongdan Zheng, Tong Wang, Zijian Zou, Wenjie Ma, Zirui Dong, Jingqin Zhong, Wanlin Liu, Yu Xu, Tu Hu, Wei Sun and Yong Chen
Biomolecules 2025, 15(6), 904; https://doi.org/10.3390/biom15060904 - 19 Jun 2025
Cited by 3 | Viewed by 3364
Abstract
Though having been discovered in one third of sarcomas, gene fusions are less studied in their roles as potential therapeutic targets, making conventional modalities the mainstream treatment options for sarcoma patients. Recent decades have witnessed encouraging progress in basic research delving into mechanisms [...] Read more.
Though having been discovered in one third of sarcomas, gene fusions are less studied in their roles as potential therapeutic targets, making conventional modalities the mainstream treatment options for sarcoma patients. Recent decades have witnessed encouraging progress in basic research delving into mechanisms underlying how gene fusions drive sarcomas; nevertheless, further translation to clinical application fails to keep abreast with the advances achieved in basic science. In this review, we will focus on key chromosomal translocation-driven sarcomas defined by characteristic hallmark fusion oncoproteins, including Ewing sarcoma with EWSR1–FLI1/ERG fusion, epithelioid hemangioendothelioma with WWTR1–CAMTA1/YAP1–TFE1 fusion, and others, to discuss the potential of directly targeting these fusion proteins as therapeutic targets in preclinical and clinical contexts. Full article
(This article belongs to the Special Issue Molecular Mechanisms and Genetics of Human Disease)
Show Figures

Figure 1

Back to TopTop